Dr. Samantha Bevill of Dana-Farber Cancer Institute presents

THIS SEMINAR HAS BEEN POSTPONED

Samantha Bevill, PhD
Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard

Seminar title: “From Transcriptional Rewiring to Therapeutic Opportunities: Targeting MDM2 Amplifications in Cancer”

Location: 4007 Genetic Medicine Building

Please join us and show support for our seminar speakers!
(For those unable to attend, a zoom link is available upon request to Mimi Baltz.)

Host: UNC Lineberger & Pharmacology Special Seminar Series

About Dr. Bevill: Samantha Bevill, PhD, is a pharmacologist specializing in the mechanisms of therapeutic resistance in aggressive cancers. She earned her B.S. in Microbiology from Clemson  university and her Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill. Under the mentorship of Dr. Gary Johnson, her doctoral research utilized advanced proteomics and genomics to map compensatory kinase signaling pathways in breast

cancer. Currently, as a postdoctoral fellow in Dr. Bradley Bernstein’s laboratory, Dr. Bevill investigates the transcriptional regulatory landscapes of aggressive sarcomas. Her work has uncovered a novel role for MDM2 in driving therapeutic resistance. Dr. Bevill’s most recent work, which is co-advised by Dr. Jun Qi, bridges basic mechanistic

discovery and therapeutic application, developing chemical biology strategies to leverage MDM2’s E3 ligase activity for tumor-specific protein degradation.